Hydroxytyrosol

DB12771

small molecule investigational

Deskripsi

Hydroxytyrosol has been used in trials studying the prevention of Breast Cancer.

Struktur Molekul 2D

Berat 154.1632
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

417 Data
Apixaban The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Apixaban.
Dasatinib Dasatinib may increase the anticoagulant activities of Hydroxytyrosol.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Hydroxytyrosol.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Ibritumomab tiuxetan.
Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Hydroxytyrosol.
Obinutuzumab The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Obinutuzumab.
Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Hydroxytyrosol.
Rivaroxaban Hydroxytyrosol may increase the anticoagulant activities of Rivaroxaban.
Tipranavir Tipranavir may increase the antiplatelet activities of Hydroxytyrosol.
Urokinase Hydroxytyrosol may increase the anticoagulant activities of Urokinase.
Vitamin E Vitamin E may increase the antiplatelet activities of Hydroxytyrosol.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Hydroxytyrosol.
Limaprost Limaprost may increase the antiplatelet activities of Hydroxytyrosol.
Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Hydroxytyrosol.
Tositumomab The risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Tositumomab.
Lepirudin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Alteplase.
Reteplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Fondaparinux.
Warfarin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Warfarin.
Phenprocoumon The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Epoprostenol.
Acenocoumarol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Prasugrel.
Sulodexide The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Astaxanthin.
Otamixaban The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Amediplase.
Danaparoid The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Tinzaparin.
(R)-warfarin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Ditazole.
Vorapaxar The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Vorapaxar.
Edoxaban The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Edoxaban.
Sodium citrate The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Sodium citrate.
Dextran The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Dextran.
Bemiparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Bemiparin.
Parnaparin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Parnaparin.
Desirudin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Desirudin.
Antithrombin Alfa The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Antithrombin Alfa.
Protein C The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Protein C.
Antithrombin III human The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Antithrombin III human.
Letaxaban The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Letaxaban.
Darexaban The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Darexaban.
Betrixaban The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Betrixaban.
Nafamostat The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Nafamostat.
Monteplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Monteplase.
Gabexate The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Gabexate.
Fluindione The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Fluindione.
Protein S human The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Protein S human.
Brinase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Brinase.
Clorindione The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Tioclomarol.
Melagatran The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Melagatran.
Saruplase The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Saruplase.
(S)-Warfarin The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with (S)-Warfarin.
Tocopherylquinone The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Tocopherylquinone.
Dabigatran The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Dabigatran.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul